Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 3Phase 4 2Phase 2 2Phase NA 1Phase 3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2

Interventions

Dexamethasone 12Bevacizumab 9Saline Solution 8Bupivacaine 8Tobacco Use Cessation Devices 7Specimen Handling 7Nivolumab 7Magnetic Resonance Spectroscopy 7Rituximab 6Prednisone 6Letrozole 6Lenalidomide 6Fluorouracil 6Cisplatin 6Carboplatin 6pembrolizumab 5Sodium Chloride 5Ropivacaine 5Human Papillomavirus Recombinant Vaccine nonavalent 5Trastuzumab 4Tamoxifen 4Standard of Care 4Propofol 4Paclitaxel 4Immune Checkpoint Inhibitors 4Esomeprazole 4Enoxaparin 4Doxorubicin 4Bortezomib 4Bismuth 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Zoledronic Acid × 1 year × Clear all
NCT04549207 2026-04-07

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

Ottawa Hospital Research Institute

Phase 4 Active not recruiting
240 enrolled
Breast

Breast Neoplasms

NCT03664687 2026-02-09

REaCT-ZOL

Ottawa Hospital Research Institute

Phase 4 Completed
211 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡